Charron L Long
Overview
Explore the profile of Charron L Long including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryan J, Franklin S, Canterberry M, Long C, Bowe A, Roy B, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e239316.
PMID: 37083665
Importance: Recent research highlights the association of social determinants of health with health outcomes of patients with type 2 diabetes (T2D). Objective: To examine associations between health-related social needs (HRSNs)...
2.
Powers B, Long C, Franklin S
Health Aff (Millwood)
. 2022 Oct;
41(10):1530.
PMID: 36190878
No abstract available.
3.
Canterberry M, Figueroa J, Long C, Hagan A, Gondi S, Bowe A, et al.
JAMA Health Forum
. 2022 Aug;
3(7):e221874.
PMID: 35977222
Importance: There is increased focus on identifying and addressing health-related social needs (HRSNs). Understanding how different HRSNs relate to different health outcomes can inform targeted, evidence-based policies, investments, and innovations...
4.
Long C, Franklin S, Hagan A, Li Y, Rastegar J, Glasheen B, et al.
Health Aff (Millwood)
. 2022 Apr;
41(4):557-562.
PMID: 35377752
Among older adults enrolled in Medicare Advantage, health-related social needs are highly prevalent, with financial strain, food insecurity, and poor housing quality the most commonly reported. The distribution of health-related...
5.
Billings J, Racsa P, Bordenave K, Long C, Ellis J
Int J Clin Pract
. 2018 May;
72(6):e13088.
PMID: 29767472
Background: Pharmacogenomics is intended to help clinicians provide the right drug to the right patient at an appropriate dose. However, limited evidence of clinical utility has slowed uptake of pharmacogenomic...
6.
Raebel M, Lyons E, Andrade S, Chan K, Chester E, Davis R, et al.
J Gen Intern Med
. 2006 Jan;
20(12):1120-6.
PMID: 16423101
Background And Objectives: Product labeling and published guidelines reflect the importance of monitoring laboratory parameters for drugs with a risk of organ system toxicity or electrolyte imbalance. Limited information exists...
7.
Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial
Raebel M, Lyons E, Chester E, Bodily M, Kelleher J, Long C, et al.
Arch Intern Med
. 2005 Nov;
165(20):2395-401.
PMID: 16287769
Background: The importance of laboratory monitoring for drugs is reflected in product labeling and published guidelines, but monitoring recommendations are followed inconsistently. Opportunity exists to improve monitoring, with the potential...
8.
Long C, Raebel M, Price D, Magid D
Ann Pharmacother
. 2004 Apr;
38(5):853-8.
PMID: 15054147
Objective: To assess the level of reported compliance with renal dosing guidelines in inpatient, long-term care, and ambulatory settings. Data Sources: Available databases (MEDLINE, Cochrane Central Register of Controlled Trials,...